Document is current

Article History

Received: 19 May 2025

Accepted: 23 July 2025

First Online: 5 August 2025

Declarations

:

: Not applicable since this a position manuscript.

: All authors have agreed to this publication.

: Christian S. Scheer discloses funding from European Sepsis Alliance for conducting the European Sepsis Care Survey and funding from Becton and Dickinson for technical realisation of the project. Antonio Artigas discloses a BIOVAP-2 PSP study grant from Abionic; a Septibell study grant from Loop-Dx; Consulting fees from Grifols for Evaluation Albus awards, Fabentech for Scientific advisor of EPIC-CROWN-2 project, Lilly Foundation for Scientific Advisor committee, Aerogen for Spanish Advisory meeting; Board participation ImmuneSep (DSMB Committee), Apeptico (DSMB Committee), Exvastat (Scientific Advisor Board). Konrad Reinhart discloses holding shares from InflaRx NV, which is based in Jena, Germany and listed at NASDQ. He is the Founding President of the Global Sepsis Alliance. Adam Linder has nothing to disclose. E. J. Giamarellos-Bourboulis has received honoraria from Abbott Products Operations AG, bioMérieux Inc, Sobi, and ThermoFisher Brahms GmbH; independent educational grants from Abbott Products Operations, bio Mérieux Inc, Gentian, InCyte, MSD, Novartis, UCB, PHC Europe BV, Swedish Orphan Biovitrum AB (publ) (Sobi); and funding from the Horizon 2020 European Grants ImmunoSep and RISCinCOVID and the Horizon Health grant EPIC-CROWN-2, Homi-LUNG and POINT (granted to the Hellenic Institute for the Study of Sepsis or to the National and Kapodistrian University of Athens). The other authors do not report any conflict of interest.